Claims for Patent: 10,793,547

Summary for Patent: 10,793,547

Title:	Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Abstract:	Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
Inventor(s):	Alexander Russell Abela, Timothy Alcacio, Corey Anderson, Paul Timothy Angell, Minson Baek, Jeremy J. Clemens, Thomas Cleveland, Lori Ann Ferris, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Robert M. Hughes, Pramod Virupax Joshi, Ping Kang, Ali Keshavarz-Shokri, Haripada Khatuya, Paul John Krenitsky, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Jean Denis Pierre, Yi Shi, Muna Shrestha, David Andrew Siesel, Kathy Stavropoulos, Andreas P. Termin, Fredrick F. Van Goor, Johnny Uy, Timothy John Young, Jinglan Zhou
Assignee:	Vertex Pharmaceuticals San Diego LLC , Vertex Pharmaceuticals Inc
Application Number:	US15/836,627
Patent Claims:	1. A compound selected from Compound I: deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing. 2. A compound selected from the following formula: a pharmaceutically acceptable salt thereof, and a deuterated derivative of any of the foregoing. 3. A compound of the following formula: 4. A pharmaceutical composition comprising: (a) a compound of the following formula: and (b) a pharmaceutically acceptable carrier. 5. The pharmaceutical composition of claim 4 further comprising Compound II: 6. The pharmaceutical composition of claim 4 further comprising Compound III: 7. The pharmaceutical composition of claim 5 further comprising Compound III: 8. A method of treating cystic fibrosis comprising administering to a patient in need thereof a compound of the following formula: 9. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition comprising: (a) a compound of the following formula: and (b) a pharmaceutically acceptable carrier. 10. A pharmaceutically acceptable salt of Compound 1: 11. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable salt of Compound I: and (b) a pharmaceutically acceptable carrier. 12. The pharmaceutical composition of claim 11, further comprising Compound II: 13. The pharmaceutical composition of claim 11, further comprising Compound III: 14. The pharmaceutical composition of claim 12, further comprising Compound III: 15. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutically acceptable salt of Compound 1: 16. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition of claim 12. 17. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition of claim 13. 18. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition of claim 14. 19. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition of claim 5. 20. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition of claim 6. 21. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition of claim 7.